Epilepsy Surgery Market by Procedure Type, End-User, and Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2034
Overview
Epilepsy Surgery Market size was valued at US$ 1.27 Bn. in 2025 and the total revenue is expected to grow at 6.10% through 2026 to 2034, reaching nearly US$ 2.17Bn.
Epilepsy Surgery Market Overview:
Epilepsy surgery is a type of neurosurgery that involves treating the parts of the brain that cause seizures. The operation is performed in order to lessen or eliminate the risk of seizures. The rise of the epilepsy surgery market can be ascribed to the rising incidence of neurological disorders, which has resulted in substantial research and development on epilepsy treatment devices, as well as an increase in the number of cases of brain injuries caused by car accidents. Technological advancements in robot-assisted surgery, as well as an increase in the geriatric population, are expected to fuel market growth. Risks connected with epilepsy surgery, on the other hand, may limit market expansion.
Epilepsy Surgery Market Size, Growth & Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Epilepsy Surgery Market Dynamics:
Epilepsy affects roughly 50 million people worldwide, according to the WHO's 2019 fact sheets, making it one of the most frequent neurological diseases. Epilepsy affects about 80% of people in low- and middle-income nations. If properly diagnosed and treated, it is believed that up to 70% of persons with epilepsy could live seizure-free. After migraines, strokes, and Alzheimer's disease, epilepsy is the fourth most frequent neurological condition. In 2015, the Centers for Disease Control and Prevention (CDC) anticipated that 1.3 % of the US population (3.4 million) had active epilepsy this factor further motivated the epilepsy surgery market.
Adult epileptic patients at the University of Gondar Referral Hospital in Ethiopia were evaluated in a study published in Sage Open Medicine in 2018. A total of 79 adverse events were reported as a result of the drug, including exhaustion and gastrointestinal disturbance. Anticonvulsants, often known as antiepileptic medicines, are a class of pharmacological compounds that are used to treat epileptic seizures.
The epilepsy surgery market is being bolstered by the increasing deployment of helper robots for efficient and accurate surgical planning and navigation. Patients choose minimally invasive procedures because they have a lower risk of complications, better patient outcomes, and a shorter recovery period. To remove epilepsy diseases, epilepsy surgery requires equipment such as stereo electro encephalography (SEEG), biopsy, thermal ablation of seizure foci or tumors, and deep brain stimulation (DBS).
Furthermore, before the adoption of computer-guided robotic arms adopted from the automobile sector for neurosurgery use, specialized stereotactic frames were used. SEEG is a collaborative effort between neurologists and neurosurgeons to design a basic strategy based on a noninvasive presurgical epilepsy workup. A typical 10-electrode montage can yield more than 150 recording locations. In the pediatric population, robotic stereotactic aid for neurosurgery has been documented occasionally.
Epilepsy Surgery Market Segment Analysis:
The Laser Interstitial Thermal Therapy (LITT) segment is dominating the Procedure Type segment of the Epilepsy Surgery Market:
LITT (Laser Interstitial Thermal Therapy) is a minimally invasive procedure for treating drug-resistant epilepsy and seizures that are unresponsive to medication. LITT may help some people with focal seizures that originate in a single area of the brain. The LITT procedure usually takes three to four hours. Ablation of neurological soft tissue is now possible thanks to the development of MRI-guided LITT systems.
Respective surgery is likely to grab a significant growth of the Epilepsy Market in the forecast timeframe. A little piece of the brain is removed during resective surgery. The surgeon removes brain tissue from the area of the brain where seizures occur, which is frequently a tumor, brain damage, or abnormality. It is the most often performed epilepsy surgery. Around 70% of persons who have temporal lobe surgery say that it ends their seizures. Additionally, 20% report a reduction in the frequency of their seizures. Despite being on one year of medication with an acceptable dose of antiepileptic medicine, epilepsy surgery is recommended in 30% to 40% of individuals with refractory seizure disorders.
The Hospital and Clinics segment is considered to supplement the growth of the Epilepsy Surgery Market.
In terms of end-users, hospitals and clinics dominate the epilepsy surgery market. This increase is primarily due to an increase in the number of people being diagnosed with epilepsy and receiving epilepsy surgery. Patients choose to be treated in the hospital because advanced and comprehensive treatments are offered. Clinics are also medical care facilities that treat epilepsy patients. Europe, the Americas, and developing countries such as India, China, and Russia are among the countries with the most hospitals giving treatment for this disease. Moreover, the rise in industrialization, growing population, and increasing per capita income are the factors boosting the expansion of hospitals and clinics in the forecast period.
Epilepsy Surgery Market Regional Insights:
North America is likely to boost the growth of the Epilepsy Surgery Market.
Due to a variety of elements, including the availability of well-established healthcare facilities, the high prevalence of neurological illnesses, and the rising incidence of epilepsy, the Americas dominated the epilepsy surgery market. The US. and Canada are the major countries of North America. A central nervous system (CNS) illness, which produces seizures and is the fourth most prevalent neurological disease, is believed to affect approximately 150,000 Americans.
The incidence rate is also observed to be highest in small children under the age of two and individuals aged 65 and over. Epilepsy is becoming more common in the Americas. Seizures afflict around 300,000 Canadians, and one in every 2,000 persons is diagnosed with epilepsy each year. In the Canadian population, neurological illnesses are also among the top causes of disability.
The objective of the report is to present a comprehensive analysis of the Epilepsy Surgery Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Epilepsy Surgery Market dynamics, structure by analyzing the market segments and project the Epilepsy Surgery Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Epilepsy Surgery Market make the report investor’s guide.
Epilepsy Surgery Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 15 July 2025 | Monteris Medical | Monteris Medical announced the publication of the largest prospective study to date in JAMA Neurology evaluating Laser Interstitial Thermal Therapy (LITT) for drug-resistant epilepsy using the NeuroBlate System. | This landmark study encompassing 145 patients across 15 U.S. institutions sets a new benchmark for minimally invasive surgical ablation efficacy and safety. |
| 24 February 2025 | Medtronic | Medtronic secured U.S. FDA approval for its BrainSense Adaptive deep brain stimulation (aDBS) system designed for advanced neuro-modulation treatments. | The closed-loop system advances neurological disease management by self-adjusting therapy in real-time to match individual brain activity patterns. |
| 03 December 2025 | LivaNova | LivaNova highlighted groundbreaking real-world evidence from its CORE-VNS study at the American Epilepsy Society Annual Meeting, showcasing outcomes of Vagus Nerve Stimulation (VNS) therapy. | The comprehensive multi-national data demonstrated a median reduction of up to 95% in severe disabling seizures, validating early intervention benefits for drug-resistant epilepsy. |
Epilepsy Surgery Market Scope: Inquire before buying
| Global Epilepsy Surgery Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $1.27 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 6.10% | Market Size in 2034: | US $ 2.17 Bn. |
| Segments Covered: | by Procedure Type | Resective Surgery Laser Interstitial Thermal Therapy (LITT), Other |
|
| by End-User | Hospitals & Clinics Specialty Centers |
||
Epilepsy Surgery Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Epilepsy Surgery Market Key Player
1.Novartis AG
2.Pfizer Incorporated
3.Glaxo Smith Kline Plc
4.Stryker (US)
5.Zimmer Biomet Holdings Inc. (US)
6.Auris Health, Inc. (Hansen Medical, Inc.) (US)
7.Intuitive Surgical (US)
8.Medtronic Plc (Mazor Robotics) (Ireland)
9.Cephalon, Inc. (US)
10.CMR Surgical (UK)
11.Natus Medical Incorporated (US)
12.Livanova Plc (UK)
13.Monteris Medical (US)
14.Pfizer, Inc.
15.UCB S.A
16.Bausch Health Companies Inc.
17.Teva Pharmaceutical Industries Ltd.
18.Sunovion Pharmaceuticals Inc.
Frequently Asked Questions:
1. Which region has the largest share in Global Epilepsy Surgery Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Epilepsy Surgery Market?
Ans: The Global Epilepsy Surgery Market is expected to grow at a CAGR of 6.10% during forecast period 2026-2034.
3. What is scope of the Global Epilepsy Surgery market report?
Ans: Global Epilepsy Surgery Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Epilepsy Surgery market?
Ans: The important key players in the Global Epilepsy Surgery Market are – , Novartis AG, Pfizer Incorporated, Glaxo Smith Kline Plc, Stryker (US), Zimmer Biomet Holdings Inc. (US), Auris Health, Inc. (Hansen Medical, Inc.) (US), Intuitive Surgical (US), Medtronic Plc (Mazor Robotics) (Ireland), Cephalon, Inc. (US), CMR Surgical (UK), Natus Medical Incorporated (US), Livanova Plc (UK), Monteris Medical (US), Pfizer, Inc., UCB S.A, Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., and Sunovion Pharmaceuticals Inc.
5. What is the study period of this market?
Ans: The Global Epilepsy Surgery Market is studied from 2020 to 2034.